
Brainsway (BWAY) Stock Forecast & Price Target
Brainsway (BWAY) Analyst Ratings
Bulls say
BrainsWay Ltd. has demonstrated significant growth potential, as evidenced by a 43% year-over-year increase in remaining performance obligations, now totaling approximately $70 million. Additionally, the company experienced a 27% rise in the shipment of Deep TMS systems during the fourth quarter of 2025, further supporting its revenue forecast, which has been modestly adjusted upward for 2026 to $66.8 million and projected for 2027 at $81.2 million. The favorable market response following the ProlivRx approval and strategic investments, coupled with the positive trajectory in operating performance, contribute to a robust outlook for the company's financial health and growth.
Bears say
The analysis of BrainsWay Ltd. indicates significant concerns regarding its financial outlook, primarily due to several identified risks. Key factors contributing to this negative perspective include the slower-than-expected adoption of Deep TMS systems, challenges in expanding reimbursement and market access, and difficulties in advancing into additional treatment indications. Additionally, there is a looming risk of long-term dilution, which could further undermine shareholder value.
This aggregate rating is based on analysts' research of Brainsway and is not a guaranteed prediction by Public.com or investment advice.
Brainsway (BWAY) Analyst Forecast & Price Prediction
Start investing in Brainsway (BWAY)
Order type
Buy in
Order amount
Est. shares
0 shares